227 related articles for article (PubMed ID: 29107686)
1. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance.
Chou S
Antiviral Res; 2017 Dec; 148():1-4. PubMed ID: 29107686
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.
Chou S
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827420
[TBL] [Abstract][Full Text] [Related]
3. New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
Chou S; Satterwhite LE; Ercolani RJ
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914965
[TBL] [Abstract][Full Text] [Related]
4. First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure.
Muller C; Tilloy V; Frobert E; Feghoul L; Garrigue I; Lepiller Q; Mirand A; Sidorov E; Hantz S; Alain S
Antiviral Res; 2022 Aug; 204():105361. PubMed ID: 35690130
[TBL] [Abstract][Full Text] [Related]
5. De Novo Genotypic Heterogeneity in the UL56 Region in Cytomegalovirus-Infected Tissues: Implications for Primary Letermovir Resistance.
Jo H; Kwon DE; Han SH; Min SY; Hong YM; Lim BJ; Lee KH; Jo JH
J Infect Dis; 2020 Apr; 221(9):1480-1487. PubMed ID: 31802131
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir.
Goldner T; Zimmermann H; Lischka P
Antiviral Res; 2015 Apr; 116():48-50. PubMed ID: 25637709
[TBL] [Abstract][Full Text] [Related]
7. Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.
Chou S
Antimicrob Agents Chemother; 2015 Oct; 59(10):6588-93. PubMed ID: 26259791
[TBL] [Abstract][Full Text] [Related]
8. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
9. In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products.
Komatsu TE; Hodowanec AC; Colberg-Poley AM; Pikis A; Singer ME; O'Rear JJ; Donaldson EF
Antiviral Res; 2019 Sep; 169():104549. PubMed ID: 31279814
[TBL] [Abstract][Full Text] [Related]
10. Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir.
Lischka P; Zhang D; Holder D; Zimmermann H
Antiviral Res; 2016 Aug; 132():204-9. PubMed ID: 27345658
[TBL] [Abstract][Full Text] [Related]
11. Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism.
Pilorgé L; Burrel S; Aït-Arkoub Z; Agut H; Boutolleau D
Antiviral Res; 2014 Nov; 111():8-12. PubMed ID: 25194992
[TBL] [Abstract][Full Text] [Related]
12. Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
Douglas CM; Barnard R; Holder D; Leavitt R; Levitan D; Maguire M; Nickle D; Teal V; Wan H; van Alewijk DCJG; van Doorn LJ; Chou S; Strizki J
J Infect Dis; 2020 Mar; 221(7):1117-1126. PubMed ID: 31781762
[TBL] [Abstract][Full Text] [Related]
13. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Jung S; Michel M; Stamminger T; Michel D
BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
[TBL] [Abstract][Full Text] [Related]
14. Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing.
Chou S; Kleiboeker S
Antiviral Res; 2022 Nov; 207():105422. PubMed ID: 36170912
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228).
Lischka P; Michel D; Zimmermann H
J Infect Dis; 2016 Jan; 213(1):23-30. PubMed ID: 26113373
[TBL] [Abstract][Full Text] [Related]
16. Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.
Santos Bravo M; Tilloy V; Plault N; Palomino SS; Mosquera MM; Navarro Gabriel M; Fernández Avilés F; Suárez Lledó M; Rovira M; Moreno A; Linares L; Bodro M; Hantz S; Alain S; Marcos MÁ
Microbiol Spectr; 2022 Apr; 10(2):e0019122. PubMed ID: 35343771
[No Abstract] [Full Text] [Related]
17. Drug-resistant cytomegalovirus: clinical implications of specific mutations.
Razonable RR
Curr Opin Organ Transplant; 2018 Aug; 23(4):388-394. PubMed ID: 29794552
[TBL] [Abstract][Full Text] [Related]
18. The human cytomegalovirus terminase complex as an antiviral target: a close-up view.
Ligat G; Cazal R; Hantz S; Alain S
FEMS Microbiol Rev; 2018 Mar; 42(2):137-145. PubMed ID: 29361041
[TBL] [Abstract][Full Text] [Related]
19. Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in
Piret J; Goyette N; Boivin G
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807919
[TBL] [Abstract][Full Text] [Related]
20. Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.
Hecke SV; Calcoen B; Lagrou K; Maertens J
Future Microbiol; 2019 Feb; 14():175-184. PubMed ID: 30644320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
